| 08/12 | Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scruti.. | PR |
| 08/12 | J&J to end sales of baby powder with talc globally next year | AQ |
| 08/12 | There are two ways to see inflation data | |
| 08/12 | Johnson & Johnson To Discontinue Selling Talc-Based Baby Powder In 2023 | MT |
| 08/12 | MARKETSCREENER'S WORLD PRESS REVIEW : August 12, 2022 | |
| 08/12 | Johnson & Johnson's Janssen Secures License to WuXi's TESSA Technology | MT |
| 08/12 | Johnson & Johnson to end global sales of talc-based baby powder in 2023 | AQ |
| 08/12 | Reuters-schedule/… | RE |
| 08/11 | J&J to end sales of talc-based powder worldwide in 2023 | AQ |
| 08/11 | JOHNSON & JOHNSON : Consumer Health to Transition Global Baby Powder Portfolio to Cornstar.. | PU |
| 08/11 | US Stocks Close Mixed Thursday Following Surprise Producer Price Drop | MT |
| 08/11 | US Stocks Close Mixed Thursday Following Surprise Producer Price Drop | MT |
| 08/11 | Johnson & Johnson to Discontinue Talc-Based Baby Powder in 2023 | DJ |
| 08/11 | J&J COVID vaccine factory forced to trash even more doses | AQ |
| 08/11 | Sanofi, GSK, Pfizer Shares Fall Amid Growing Concerns Around Zantac Litigation in US | MT |
| 08/11 | MeiraGTx's Q2 Net Loss Per Diluted Share Widens; Expects Sufficient Capital Through Q4 .. | MT |
| 08/10 | UK coal mine decision delayed a second time | RE |
| 08/09 | Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Co.. | BU |
| 08/08 | Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceutical.. | BU |
| 08/08 | Johnson & Johnson Announces Executive Changes | CI |
| 08/05 | The Janssen Pharmaceutical Companies - European Commission Approves IMBRUVICA (ibrutini.. | AQ |
| 08/05 | FOCUS : 5 Stocks for Yield Lovers | |
| 08/04 | South Africa Health Regulator Flags First Death Linked to Johnson & Johnson COVID-19 Ja.. | MT |
| 08/04 | The Janssen Pharmaceutical Companies of Johnson & Johnson Announces European Commission.. | CI |
| 08/03 | DA Davidson Cuts Price Target on Johnson & Johnson to $190 From $196, Reiterates Buy/Ad.. | MT |
| 08/03 | Johnson & Johnson's Q2 Headwinds Pull Back Optimism on FY2022 Performance, D.A. Davidso.. | MT |
| 08/02 | Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conferen.. | BU |
| 08/01 | Johnson & Johnson's Janssen Pharmaceutical Secures FDA Approval for Psoriatic Arthritis.. | MT |
| 08/01 | JOHNSON & JOHNSON : STELARA® (ustekinumab) Approved by the U.S. Food and Drug Administrati.. | PU |
| 08/01 | J&J Gets FDA OK of Stelara for Pediatric Patients With Active Psoriatic Arthritis | DJ |
| 07/29 | JOHNSON & JOHNSON MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU.. | AQ |
| 07/29 | Raphe Pharmaceutique Vendor Generic & OTC Self Care Contract Manufacturing Pharmaceutic.. | AQ |
| 07/27 | Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT and Lazertinib C.. | AQ |
| 07/26 | Plaintiffs Call J&J Talc Subsidiary Estimation Bid 'A Road to Nowhere' | DJ |
| 07/26 | JOHNSON & JOHNSON : Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT.. | PU |
| 07/25 | Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI (teclista.. | AQ |
| 07/25 | Greenback to hit US firms as Wall Street feels chill | AQ |
| 07/22 | Johnson & Johnson Unit Says EMA Panel Backs Conditional Marketing Approval of Bone Marr.. | MT |
| 07/22 | Janssen Gets Positive CHMP Opinion for Tecvayli to Treat Blood Cancer | DJ |
| 07/21 | UBS Adjusts Johnson & Johnson Price Target to $180 From $185, Maintains Neutral Rating | MT |
| 07/20 | JOHNSON & JOHNSON : 2022 Second-Quarter Earnings Transcript | PU |
| 07/20 | Wall Street Sees Cautiously Lower Open, Consolidating After Earnings Rally | MT |
| 07/20 | Goldman Sachs Adjusts Price Target for Johnson & Johnson to $182 From $183, Maintains N.. | MT |
| 07/20 | Atlantic Equities Adjusts Price Target on Johnson & Johnson to $165 From $174, Maintain.. | MT |
| 07/20 | SVB Securities Adjusts Price Target on Johnson & Johnson to $194 From $200, Keeps Outpe.. | MT |
| 07/20 | US Futures in Holding Pattern, Consolidating After Earnings Rally | MT |
| 07/20 | Raymond James Adjusts Price Target on Johnson & Johnson to $192 From $196, Keeps Outper.. | MT |
| 07/20 | Citigroup Adjusts Price Target on Johnson & Johnson to $201 From $205, Maintains Buy Ra.. | MT |
| 07/20 | SOCIAL BUZZ : Wallstreetbets Stocks Up Premarket; Netflix Poised to Rise After Reporting Q.. | MT |
| 07/20 | MORE TEARS : Johnson & Johnson cuts sales and profit forecasts | AQ |
| 07/19 | US Stocks Notch Solid Gains Tuesday Amid Strong Corporate Earnings | MT |
| 07/19 | ALEX GORSKY : JPMorgan adds former J&J chief Gorsky to board | RE |
| 07/19 | SECTOR UPDATE : Health Care Stocks Rising on Tuesday | MT |
| 07/19 | SECTOR UPDATE : Health Care Stocks Advance in Afternoon Trading | MT |
| 07/19 | MIDDAY REPORT : US Equity Indices Advance While Treasuries Decline in Midday Trading | MT |
| 07/19 | Johnson & Johnson Cuts 2022 Outlook on 'Unfavorable' Currency Impact Despite Improved S.. | MT |
| 07/19 | Wall Street Set for Gains After Slide on Apple News | MT |
| 07/19 | SECTOR UPDATE : Health Care Stocks Climb Premarket Tuesday | MT |
| 07/19 | Johnson & Johnson Seeks Acquisitions | CI |
| 07/19 | TRANSCRIPT : Johnson & Johnson, Q2 2022 Earnings Call, Jul 19, 2022 | CI |
| 07/19 | WALL STREET STOCK EXCHANGE : To stick or not to stick with defensive stocks? That is the q.. | |
| 07/19 | Johnson & Johnson's Executive Vice President, General Counsel Michael Ullmann to Retire.. | AQ |
| 07/19 | Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2022 | AQ |
| 07/19 | Johnson & Johnson Provides Sales Guidance for the Full Year of 2022 | CI |
| 07/19 | Stocks Set to Reverse Losses as US Futures Rise Pre-Bell; Asis | MT |
| 07/19 | Strong Q2 at J&J, but outlook cut again due to dollar's rise | AQ |
| 07/19 | Wall Street Leans Forward Pre-Bell; Futures Green, Europe Even, Asia Choppy | MT |
| 07/19 | Genmab Says Net Sales of Darzalex Reach $2 Billion in Q2 | MT |
| 07/19 | JOHNSON & JOHNSON : 2Q22 Other Financial Disclosures (Excel) | PU |
| 07/19 | JOHNSON & JOHNSON : What You Need to Know About Johnson & Johnson's 2022 Second-Quarter Ea.. | PU |
| 07/19 | JOHNSON & JOHNSON : 2022 Second-Quarter Press Release & Supplemental Schedules | PU |
| 07/19 | JOHNSON & JOHNSON : 2022 Second-Quarter Infographic & Earnings Presentation | PU |
| 07/19 | JOHNSON & JOHNSON : 2Q22 Other Financial Disclosures (PDF) | PU |
| 07/19 | Johnson & Johnson Posts Higher Q2 Adjusted Earnings, Sales; Lowers Full-Year 2022 Outlo.. | MT |
| 07/19 | JOHNSON & JOHNSON : Q2 Earnings Snapshot | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
